Oncology providers’ evaluation of the use of a prostate cancer treatment decision aid versus usual information provision: Results from the PCPCC trial

2017 ◽  
Vol 5 (4) ◽  
pp. 433 ◽  
Author(s):  
Maarten Cuypers ◽  
Romy E D Lamers ◽  
Paul J M Kil ◽  
Lonneke V Van de Poll-Franse ◽  
Marieke De Vries
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Decision Aid ◽  
Controlled Trial ◽  
Treatment Decision ◽  
Information Provision ◽  
Care Providers ◽  
Online Questionnaire ◽  
Prostate Cancer Treatment ◽  
Standard Information

Objective: To compare care providers’ evaluations of an online prostate cancer treatment decision aid (DA) to an evaluation of usual information routines.Methods: Oncology care providers (urologists and nurses, n=108) enrolled in the intervention (DA) or control (standard information) arm of a cluster randomized controlled trial were invited to fill out an online questionnaire to evaluate working with the DA or to evaluate usual information provision. Response rate was 58% (n=63).  Results: The DA was provided to 368 patients and distributing care providers were supportive of the DA content and usability. Satisfaction (1-10) with the DA or standard information was comparable (M=7.8 vs M=8.1, p=0.14), although in the control arm, care providers perceived that patients already receive too much information. Time barriers were not expected or perceived. All care providers involved felt suitable to distribute DAs. Care providers with DA experience were more supportive of including DAs in clinical guidelines.Conclusion: Care providers were satisfied with the DA and reported no time barriers. However, many care providers are already satisfied with standard information materials and fear overloading patients with information.

scholarly journals Uptake and usage of an online prostate cancer treatment decision aid in Dutch clinical practice: A quantitative analysis from the Prostate Cancer Patient Centered Care trial

2018 ◽  
Vol 25 (4) ◽  
pp. 1498-1510 ◽  
Author(s):  
Maarten Cuypers ◽  
Romy ED Lamers ◽  
Paul JM Kil ◽  
Julia J van Tol-Geerdink ◽  
Cornelia F van Uden-Kraan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patient ◽  
Cancer Treatment ◽  
Decision Aid ◽  
Prostate Cancer Patient ◽  
Decision Aids ◽  
Treatment Decision ◽  
Patient Centered ◽  
Prostate Cancer Treatment ◽  
Centered Care

Implementation of patient’s decision aids in routine clinical care is generally low. This study evaluated uptake and usage of a novel Dutch web-based prostate cancer treatment decision aid within the Prostate Cancer Patient Centered Care trial. From an estimated total patient sample of 1006 patients, 351 received a decision aid (35% implementation rate; hospital ranges 16%–84%). After receipt of the decision aid, most patients accessed the decision aid, utilized most functions, although not completely, and discussed the decision aid summary in a subsequent consultation with their care provider. Including nurses for dissemination of decision aids seemed to positively affect decision aid uptake. Once received, patients seemed able to use the decision aid and engage in shared decision-making as intended; however, decision aid uptake and complete usage of all decision aid components should be further improved. Prior to the diagnosis consultation, handing out of the decision aid should be prepared.

627 A RANDOMIZED PILOT STUDY TO ASSESS ANXIETY RELATED TO DISTRIBUTING A PROSTATE CANCER TREATMENT DECISION AID PRIOR TO BIOPSY

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Steven Zeliadt ◽  
Laura Bonner ◽  
Ranak Trivedi ◽  
Crystal Kimmie ◽  
Peggy Hannon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Cancer Treatment ◽  
Decision Aid ◽  
Treatment Decision ◽  
Prostate Cancer Treatment

scholarly journals PD40-02 STATEWIDE IMPLEMENTATION OF PROSTATE CANCER TREATMENT DECISION AID IN MICHIGAN

2020 ◽  
Vol 203 ◽  
pp. e815
Author(s):  
Roshan Paudel* ◽  
Stephanie Ferrante ◽  
Donna Berry ◽  
Jessica Woodford ◽  
Conrad Maitland ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Decision Aid ◽  
Treatment Decision ◽  
Prostate Cancer Treatment

scholarly journals Seeking Mind, Body and Spirit Healing–-Why Some Men with Prostate Cancer Choose CAM (Complementary and Alternative Medicine) over Conventional Cancer Treatments

2008 ◽  
Vol 3 ◽  
pp. IMI.S377 ◽  
Author(s):  
Margaret A. White ◽  
Marja J. Verhoef ◽  
B.J. Davison ◽  
Hal Gunn ◽  
Karen Cooke
Keyword(s):  
Prostate Cancer ◽  
Alternative Medicine ◽  
Cancer Treatment ◽  
Complementary And Alternative Medicine ◽  
Health Care Providers ◽  
Conventional Treatment ◽  
Lifestyle Changes ◽  
Care Providers ◽  
Prostate Cancer Treatment ◽  
Complementary And Alternative

Little is known about men with prostate cancer who decline conventional treatment and use only complementary and alternative medicine (CAM). Objectives To 1) explore why men decline conventional prostate cancer treatment and use CAM 2) understand the role of holistic healing in their care, and 3) document their recommendations for health care providers. Methods Semi-structured interviews and follow-up focus groups. Sample Twenty-nine men diagnosed with prostate cancer who declined all recommended conventional treatments and used CAM. Results Based on strong beliefs about healing, study participants took control by researching the risks of delaying or declining conventional treatment while using CAM as a first option. Most perceived conventional treatment to have a negative impact on quality of life. Participants sought healing in a broader mind, body, spirit context, developing individualized CAM approaches consistent with their beliefs about the causes of cancer. Most made significant lifestyle changes to improve their health. Spirituality was central to healing for one-third of the sample. Participants recommended a larger role for integrated cancer care. Conclusion Men who decline conventional prostate cancer treatment and use CAM only may benefit from a whole person approach to care where physicians support them to play an active role in healing while carefully monitoring their disease status.

Abstract A047: An ethnographic study of African American men's prostate cancer treatment decision-making

2020 ◽  
Author(s):  
Nynikka R. Palmer ◽  
Richard L. Street ◽  
Dean Schillinger ◽  
Janet K. Shim ◽  
Sarah D. Blaschko ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
African American ◽  
Cancer Treatment ◽  
Treatment Decision ◽  
Ethnographic Study ◽  
Prostate Cancer Treatment ◽  
Treatment Decision Making

scholarly journals To Share or Not to Share: Malaysian Healthcare Professionals' Views on Localized Prostate Cancer Treatment Decision Making Roles

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142812 ◽  
Author(s):  
Yew Kong Lee ◽  
Ping Yein Lee ◽  
Ai Theng Cheong ◽  
Chirk Jenn Ng ◽  
Khatijah Lim Abdullah ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
Cancer Treatment ◽  
Healthcare Professionals ◽  
Treatment Decision ◽  
Localized Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
Treatment Decision Making

scholarly journals Comparing Prostate Cancer Treatment Decision Making in a Resource-rich and a Resource-poor Environment: A Tale of two Hospitals

2016 ◽  
Vol 108 (4) ◽  
pp. 211-219 ◽  
Author(s):  
Daniel M. Walker ◽  
Ann Scheck McAlearney ◽  
Lindsey N. Sova ◽  
Jenny J. Lin ◽  
Sarah Abramson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
Cancer Treatment ◽  
Treatment Decision ◽  
Prostate Cancer Treatment ◽  
Treatment Decision Making ◽  
Resource Poor

Patterns of prostate cancer management across Canadian prostate cancer treatment specialists.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 321-321
Author(s):  
Bobby Shayegan ◽  
Alan I. So ◽  
Shawn Malone ◽  
Sebastien J. Hotte ◽  
Antonio Finelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Advanced Prostate Cancer ◽  
Patterns Of Care ◽  
Online Questionnaire ◽  
Prostate Cancer Treatment ◽  
Chi Square ◽  
Cancer Management ◽  
Radiation Oncologists ◽  
Medical Oncologists

321 Background: The Canadian GU Research Consortium (GURC) was recently established to bring comprehensive prostate cancer centres together to collaborate on research, education, and adoption of best practices. As an initial step to inform the work of the GURC, an electronic questionnaire was designed to assess management of advanced prostate cancer care in Canada and better understand patterns of care. Methods: A 59-item online questionnaire was developed by a multidisciplinary scientific committee to measure physician practices, patterns of care, treatment sequencing, and management of mCRPC. After pre-testing, the online questionnaire was sent to 93 urologists, uro-oncologists, medical oncologists, radiation oncologists, and general practitioner oncologists who are actively involved in the treatment of prostate cancer. Results: A total of 49 (53%) respondents completed the questionnaire between April 17, 2017 to May 17, 2017. Although all respondents indicated a role in initiating life-prolonging oral therapy for mCRPC and monitoring treatment and side effects, chemotherapy initiation was mainly a medical oncologist role compared to other specialties (p < 0.05, chi-square). Symptom management such as palliative care and end-of-life care were provided mainly by radiation oncologists (100%) and medical oncologists (81%) compared to urologists (33%) and uro-oncologists (50%), p < 0.05, chi-square). Patient mix varied across the disciplines. Urologist practices were composed primarily of non-metastatic prostate cancer patients (73%), as were radiation oncologist practices (77%), while uro-oncologist practices included both non-metastatic (58%) and metastatic (40%) patients. Medical oncologists practices were mainly (91%) metastatic patients. Referral patterns also varied by discipline. Conclusions: In Canada, prostate cancer treatment involves multiple disciplines providing a range of care at different points across the treatment continuum. We plan to do further research to better understand variation in practice and improve multidisciplinary coordination for patients with advanced prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document